CHONGKUNDANG HOLDINGS CORP.
Financials
Valuation Metrics
CHONGKUNDANG HOLDINGS CORP.'s Market Cap is ₩1961B. At end of 2025 it was ₩2317B. Ranked #832 of 2,436 in KR market (top 34%), #451 of 787 on KOSPI (top 57%), #91 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 196.14B KRW | KR#832/2,436 Sec#91/234 |
| Revenue | 952.66B KRW | KR#415/2,436 Sec#16/234 |
| Net Income | 64.37B KRW | KR#308/2,436 Sec#22/234 |
| Total Assets | 1.68T KRW | KR#330/2,436 Sec#14/234 |
| Net Assets | 923.72B KRW | KR#298/2,436 Sec#19/234 |
| Employees | 37 | KR#2,130/2,436 Sec#195/234 |
| Value | ||
| P/E | 3.05x | KR#115/2,436 Sec#5/234 |
| P/B | 0.21x | KR#136/2,436 Sec#4/234 |
| PEG | 0.02x | KR#154/2,436 Sec#5/234 |
| P/S | 0.21x | KR#386/2,436 Sec#7/234 |
| EV/EBITDA | 10.98x | KR#659/2,436 Sec#32/234 |
| FCF Yield | 10.30% | KR#616/2,436 Sec#23/234 |
| Profitability | ||
| ROE | 6.97% | KR#794/2,436 Sec#58/234 |
| ROA | 3.83% | KR#818/2,436 Sec#73/234 |
| Op. Margin | 6.89% | KR#713/2,436 Sec#60/234 |
| Revenue Growth | -2.58% | KR#1,593/2,436 Sec#150/234 |
| Earnings Growth | 128.21% | KR#357/2,436 Sec#26/234 |
| Financial Health | ||
| Debt Ratio | 81.76% | KR#268/2,436 Sec#36/234 |
| Total Debt | 562.67B KRW | KR#277/2,436 Sec#8/234 |
| FCF | 20.20B KRW | KR#520/2,436 Sec#29/234 |
| Cash | 37.72B KRW | KR#885/2,436 Sec#57/234 |
| Current Ratio | 0.83x | KR#2,008/2,436 Sec#191/234 |
| Net Debt/EBITDA | 8.00x | KR#1,222/2,436 Sec#88/234 |
| Dividend | ||
| Div. Yield | 3.65% | KR#510/2,436 Sec#19/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -19.11% | KR#1,238/2,436 Sec#101/234 |
| 1M Return | -2.61% | KR#1,171/2,436 Sec#113/234 |
| From 52W High | -33.98% | KR#531/2,436 Sec#35/234 |
| 1Y MDD | -33.51% | KR#299/2,436 Sec#19/234 |
| Trading | ||
| Volume | 3,037 shares | KR#2,316/2,436 Sec#227/234 |
| Foreign Own. | 3.47% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 9,457 KRW | KR#92/2,436 Sec#8/234 |
| BPS | 136,062 KRW | KR#99/2,436 Sec#4/234 |
Company Info
Jonggeundang Holdings, established in 1941, became a registered pharmaceutical company in 1956 before transitioning to a holding company structure in 2013 through a spin-off of its investment and pharmaceutical divisions. As a holding company, its main revenue sources are management consulting fees, brand usage fees, and dividend income, with a focus on governance and management through subsidiary equity ownership. It manages key subsidiaries such as Jonggeundang Health, Gyeongbo Pharmaceutical, Jonggeundang Bio, and Jonggeundang Industrial, along with its subsidiary Jonggeundang, fostering synergy and value through independent management and performance evaluation. The company is headquartered in Seodaemun-gu, Seoul Metropolitan City.